通过肝动脉用溶瘤病毒靶向肝肿瘤

Executive Industry Relevance

Locoregional delivery of oncolytic viruses via the hepatic artery addresses the challenge of achieving tumor-selective virotherapy in hepatocellular carcinoma models. This approach enhances predictive confidence in tumor targeting while minimizing systemic exposure, supporting early-stage mechanistic de-risking and translational continuity. The method is positioned to inform portfolio decisions on targeted virotherapeutic strategies in preclinical oncology pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of tumor-selective viral replication and lysis mechanisms in vivo.
• Supports biological de-risking by isolating hepatic delivery effects from systemic confounders.
• Facilitates functional validation of oncolytic virus selectivity for malignant versus healthy hepatocytes.

Screening & Assay Development

• Establishes a reproducible in vivo platform for evaluating oncolytic virus efficacy in liver tumors.
• Standardizes arterial injection and ligation procedures to ensure consistent viral delivery.
• Generates quantitative outputs on tumor cell lysis and viral replication for comparative analysis.

Translational & Preclinical Research

• Aligns with disease-relevant models for hepatocellular carcinoma, supporting translational biomarker development.
• Provides continuity from mechanistic discovery to preclinical validation of locoregional virotherapy.
• Enables risk-adjusted advancement of candidates based on in vivo tumor targeting and safety profiles.

Pipeline & Workflow Integration

This hepatic artery injection method integrates into the discovery-to-preclinical continuum for oncolytic virotherapy candidates targeting liver malignancies.

• Discovery Biology: Supports hypothesis testing on tumor-selective viral replication and immunogenic cell death.
• Screening: Delivers standardized, reproducible in vivo readouts for candidate comparison.
• Analytics: Enables quantitative assessment of tumor lysis and viral distribution in targeted tissues.
• Translational Research: Bridges mechanistic findings to preclinical models with disease relevance.
• Enterprise Reuse: Provides a validated workflow adaptable to other locoregional virotherapy studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in tumor targeting and viral selectivity.
• Operational Value: Standardizes surgical and injection procedures for reproducibility and scalability.
• Strategic Value: Informs go/no-go decisions for virotherapy candidates based on in vivo efficacy and safety.
• Portfolio Impact: Enables risk-adjusted prioritization of locoregional virotherapy assets.

Implementation Considerations

• Requires expertise in small animal surgery and vascular anatomy.
• Demands access to dissecting microscopes, microinjection tools, and surgical instrumentation.
• Necessitates cross-team standardization of injection and ligation protocols.
• Adaptation may be needed for different animal models or tumor types.
• Potential limitations include technical variability and model-specific anatomical constraints.

Biopharma FAQs